The New England Journal of Medicine recently published the results of a randomized controlled clinical trial that reaffirms the estimated effectiveness of Beyfortus™ (nirsevimab), a second-generation monoclonal antibody that reduces the risk of hospitalization for respiratory syncytial virus (RSV)- associated bronchiolitis in infants by 83%.
This finding is significant since RSV is the leading cause of bronchiolitis, resulting in about three million hospitalizations each year worldwide.
Second-Gen Passive Immunization Significantly Protects Infants from RSV
First-Trimester COVID-19 Vaccine Does Not Increase Risk for Birth Defects
Receipt of mRNA COVID-19 vaccine during the first trimester not associated with an increased risk for selected major structural birth defects
In-Hospital Delirium Increases Risk for Functional Disability, Cognitive Impairment
Findings seen among older adults in the six months following a COVID-19 hospitalization